Loading
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Latest filing published 08 Jul 2021 for Acumen Pharmaceuticals, Inc..
Insider track record
Disclosed buys
2
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Robert D. Hardie: trading record in brief
This profile gathers the share dealings of Robert D. Hardie in Acumen Pharmaceuticals, Inc., where the filings describe the role as chief executive. Activity is concentrated on a single trading day, 6 July 2021, with 6 filings.
No open-market sale appears; the market trades are 2 purchases worth €14.4M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
On 8 July 2021 came the latest disclosure, an open-market purchase for €10.1M in Acumen Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Robert D. Hardie
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
2,950,484 sharesCommon StockSEC:0001209191-21-046028:0
1,124,830 sharesCommon StockSEC:0001209191-21-046027:0
2 of 2 declarations
